dc.contributor.author | Tanakol, R | |
dc.contributor.author | Dincol, G | |
dc.contributor.author | Nalcaci, M | |
dc.contributor.author | Aktan, M | |
dc.date.accessioned | 2021-03-04T11:01:59Z | |
dc.date.available | 2021-03-04T11:01:59Z | |
dc.date.issued | 2000 | |
dc.identifier.citation | Aktan M., Tanakol R., Nalcaci M., Dincol G., "Leukemia in a patient treated with growth hormone", ENDOCRINE JOURNAL, cilt.47, sa.4, ss.471-473, 2000 | |
dc.identifier.issn | 0918-8959 | |
dc.identifier.other | av_70466712-e42f-4b7a-b671-1abf867013fd | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/77400 | |
dc.identifier.uri | https://doi.org/10.1507/endocrj.47.471 | |
dc.description.abstract | It is well known that growth hormone (GH) therapy is associated with increased risk of development of malignant tumors, especially leukemia. In the case presented, growth hormone treatment was initiated in a 25-year-old patient with hypopituitarism. After 4 months of therapy with thrice a week injections of rhGH, acute It was thought that no clearcut evidence existed to establish a relationship between the growth hormone treatment and development of acute leukemia. | |
dc.language.iso | eng | |
dc.subject | İç Hastalıkları | |
dc.subject | Endokrinoloji ve Metabolizma Hastalıkları | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | ENDOKRİNOLOJİ VE METABOLİZMA | |
dc.title | Leukemia in a patient treated with growth hormone | |
dc.type | Makale | |
dc.relation.journal | ENDOCRINE JOURNAL | |
dc.contributor.department | , , | |
dc.identifier.volume | 47 | |
dc.identifier.issue | 4 | |
dc.identifier.startpage | 471 | |
dc.identifier.endpage | 473 | |
dc.contributor.firstauthorID | 126060 | |